Novel Steroidal (Thio)barbiturate Hybrids: From Design to Preclinical Assessment in Tumor Therapy
ChemMedChem · 2026
DOI: 10.1002/cmdc.70476 ↗At a glance
Journal article in ChemMedChem, 2026. Written by Alexandra Varges and 12 co-authors. Institution: RISE-Health, Department of Chemistry, Faculty of Sciences, University of Beira Interior, Covilhã, Portugal. Major MEDLINE topics: Antineoplastic Agents, Drug Design, Barbiturates. 91 references. The full text is freely available in PubMed Central. Funded by: FCT (UID/06397/2025, UID/QUI/UI0616/2019, SFRH/BD/148028/2019, SFRH/BD/147645/2019, 2020.07634.BD), PPBI-Portuguese Platform of BioImaging.
Abstract (original language)
Cancer remains a public health concern with high rates of incidence and mortality, despite the significant advances achieved in recent decades. Therefore, this study aimed to develop novel hybrid molecules with potential anticancer properties. To this end, a steroid nucleus, specifically pregnenolone or dehydroepiandrosterone (DHEA), was covalently linked to a (thio)barbiturate scaffold. The hybrid molecules showed relevant antiproliferative activity against breast (MCF‐7) and prostate (PC‐3) cancer cells (IC 50 = 8.73–38.53 and 4.08–36.01 µM, respectively), with selectivity indices of up to 2.79. The most promising compounds 4b (pregnenolone–barbiturate hybrid) and 7f (DHEA–thiobarbiturate hybrid) induced cell cycle arrest in the G0/G1 phase of breast cancer cells, with the DHEA–thiobarbiturate hybrid demonstrating a 6.6‐ and a 2.0‐fold increase in apoptotic cells compared with untreated cells and cells treated with the anticancer drug 5‐fluourouracil, respectively. Interestingly, a docking study suggested that these new hybrids may exhibit significant affinity for CYP17 and 5α‐reductase enzymes. Preliminary pharmacokinetic investigation of the most promising hybrids suggested low intestinal absorption, which may be improved through appropriate formulation strategies. Overall, these findings indicate that these novel hybrid compounds, incorporating both (thio)barbiturates and steroid nuclei, represent a promising strategy for the development of anticancer drug candidates.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- RISE-Health, Department of Chemistry, Faculty of Sciences, University of Beira Interior, Covilhã, Portugal.
- RISE-Health, Department of Medical Sciences, Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal.
ORCID profiles: Alexandra Varges, João Serrano, Pedro Soeiro, Eurico Lima, Gilberto Alves, Adriana Oliveira Santos, Renato Boto, Paulo Almeida, Samuel Silvestre, Mariana Matias
Funding
- FCT (UID/06397/2025, UID/QUI/UI0616/2019, SFRH/BD/148028/2019, SFRH/BD/147645/2019, 2020.07634.BD)
- PPBI-Portuguese Platform of BioImaging
Cite
APA
Varges, A., Serrano, J., Arias, P., Soeiro, P., Machava, M., Figueiredo, I., Lima, E., Alves, G., Santos, A. O., Boto, R., Almeida, P., Silvestre, S., & Matias, M. (2026). Novel Steroidal (Thio)barbiturate Hybrids: From Design to Preclinical Assessment in Tumor Therapy. ChemMedChem. https://doi.org/10.1002/cmdc.70476
Vancouver
Varges A, Serrano J, Arias P, Soeiro P, Machava M, Figueiredo I, et al. Novel Steroidal (Thio)barbiturate Hybrids: From Design to Preclinical Assessment in Tumor Therapy. ChemMedChem. 2026. doi:10.1002/cmdc.70476
BibTeX
@article{Varges2026,
author = {Varges, Alexandra and Serrano, João and Arias, Paula and Soeiro, Pedro and Machava, Marla and Figueiredo, Inês and Lima, Eurico and Alves, Gilberto and Santos, Adriana Oliveira and Boto, Renato and Almeida, Paulo and Silvestre, Samuel and Matias, Mariana},
title = {Novel Steroidal (Thio)barbiturate Hybrids: From Design to Preclinical Assessment in Tumor Therapy},
journal = {ChemMedChem},
year = {2026},
doi = {10.1002/cmdc.70476}
}
EUVIMED